Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide

NCT03700099 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT03700099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03700099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 2
Overall status
Unknown status
Start date
September 3, 2019
Completion date
April 1, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, prostate cancer